Zeev Bovan
Posts (688)
$NOW It wants to fly.
$BABA 200$ next year
Overreaction, it was never about a quarterly report, it’s about the soon to be approved cancer treatment drug that will make this company profitable and send the stock price up.
$ORCL screen shot this post, 1000$ in 3 years, it will increase further steadily once the investments start to print money.
Gold is going to the moon $B
Scenario 1: TARA-002 becomes a best-in-class NMIBC therapy
This is the dream outcome.
Recent data showed:
72% complete response rate at any time
67% complete response at 6 months
55% complete response at 12 months in the BCG-naïve NMIBC cohort
Favorable safety profile with no Grade 3+ treatment-related adverse events reported in that update
If future registrational trials confirm strong efficacy, investors may value TARA as a future oncology commercial company rather than a speculative biotech.
Possible valuation:
Assume:
Market Cap Approximate Stock Price*
$500M ~$9
$1B ~$18
$2B ~$36
*Approximate based on ~56M shares outstanding; actual dilution could change this.
A $1B–$2B valuation is not impossible for a biotech with a successful cancer drug, but it requires major clinical and regulatory wins.
🚀 Catalysts That Could Send TARA Higher
- ADVANCED-3 registrational trial
This is probably the biggest catalyst.
The company has said it plans to initiate the ADVANCED-3 registrational trial in BCG-naïve NMIBC patients in the second half of 2026.
A strong trial design + FDA alignment could trigger institutional buying.
Potential impact: Very High ⭐⭐⭐⭐⭐ - FDA acceleration
TARA already received Breakthrough Therapy and Fast Track designations for TARA-002 in lymphatic malformations.
More FDA support for bladder cancer could dramatically change investor perception.
Potential impact: Very High ⭐⭐⭐⭐⭐ - Partnership / buyout speculation
Large oncology companies often acquire small biotech firms after promising Phase 2/3 data.
A partnership could:
validate TARA-002
bring upfront cash
reduce financing risk
Potential impact: Extremely High ⭐⭐⭐⭐⭐ - Short squeeze / momentum
Because TARA is a small biotech, positive news could create outsized moves if liquidity is limited.
This is a trading catalyst, not a fundamental one.
Potential impact: Medium-High ⭐⭐⭐⭐
Is it just me or $BOOM chart looks like a big mess.
2 weeks this ballon goes back to where it was, dragging all the market with it, that bs pumping has to be regulated and stopped.
PE of 150? you are giving a cash advance as if Palantir is skynet dominating the world and literally sending terminators back in time, it’s ridicules for people like Buffet who saw great companies with an extraordinary stock price crash and unfortunately for the bulls this is what makes stocks moving, the big money, not the small retail investors.
